- Home
- CGO vs LXRX Comparison
CGO vs LXRX Comparison
Compare CGO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGO
- LXRX
- Stock Information
- Founded
- CGO 2004
- LXRX 1995
- Country
- CGO United States
- LXRX United States
- Employees
- CGO N/A
- LXRX N/A
- Industry
- CGO Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- CGO Finance
- LXRX Health Care
- Exchange
- CGO Nasdaq
- LXRX Nasdaq
- Market Cap
- CGO 105.3M
- LXRX 124.4M
- IPO Year
- CGO N/A
- LXRX 2000
- Fundamental
- Price
- CGO $10.39
- LXRX $0.46
- Analyst Decision
- CGO
- LXRX Buy
- Analyst Count
- CGO 0
- LXRX 4
- Target Price
- CGO N/A
- LXRX $3.67
- AVG Volume (30 Days)
- CGO 34.7K
- LXRX 30.7M
- Earning Date
- CGO 01-01-0001
- LXRX 03-06-2025
- Dividend Yield
- CGO 9.25%
- LXRX N/A
- EPS Growth
- CGO N/A
- LXRX N/A
- EPS
- CGO N/A
- LXRX N/A
- Revenue
- CGO N/A
- LXRX $31,081,000.00
- Revenue This Year
- CGO N/A
- LXRX N/A
- Revenue Next Year
- CGO N/A
- LXRX $101.91
- P/E Ratio
- CGO N/A
- LXRX N/A
- Revenue Growth
- CGO N/A
- LXRX 2481.48
- 52 Week Low
- CGO $7.90
- LXRX $0.28
- 52 Week High
- CGO $10.93
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- CGO 34.75
- LXRX 50.39
- Support Level
- CGO $10.20
- LXRX $0.32
- Resistance Level
- CGO $11.71
- LXRX $0.71
- Average True Range (ATR)
- CGO 0.16
- LXRX 0.06
- MACD
- CGO 0.00
- LXRX 0.03
- Stochastic Oscillator
- CGO 33.04
- LXRX 36.95
About CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.